Literature DB >> 28775598

EVALUATION OF PUVASOL AND PUVASOL WITH TOPICAL BETAMETHASONE DIPROPIONATE PLUS SALICYLIC ACID LOTION IN THE TREATMENT OF SCALP PSORIASIS.

P K Kar1, C V Ramasastry2, R S Dhaka3.   

Abstract

The efficacy and safety of betamethsone dipropionate 0.05% with salicylic acid 2% scalp lotion was evaluated in 60 patients with moderate to severe scalp psoriasis. Out of 120 patients with scalp psoriasis 60 patients received PUVASOL alone and 60 patients received PUVASOL alongwith lotion 0.05% betamethasone dipropionate with 2% salicylic acid scalp application for 3 weeks. The erythema, induration, scales and pruritus steadily improved in patients throughout the 3 weeks treatment course with betamethasone dipropionate with salicylic acid scalp application. At the end of therapy 84.3% of those patients receiving PUVASOL and betamethasone dipropionate-salicylic acid combination had 75% improvement of their scalp psoriasis versus 34.9% of those patients using PUVASOL alone. Complete clearing of the scalp was seen in 35% patients receiving therapy with topical betamethasone-salicylic acid and 11.6% with PUVASOL alone. Local side effects were primarily burning and stinging in 5 (83%) cases treated with topical betamethasone salicylic acid scalp application and 1 (1.6%) receiving PUVASOL alone. Combined therapy with PUVASOL and topical betamethasone dispropionate 0.05% with salicyclic acid 2% application appears to be safe and an effective treatment for scalp psoriasis.

Entities:  

Keywords:  Betamethasone dipropionate; PUVASOL; Photochemotherapy; Scalp psoriasis

Year:  2017        PMID: 28775598      PMCID: PMC5531837          DOI: 10.1016/S0377-1237(17)30263-0

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  12 in total

Review 1.  Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists.

Authors: 
Journal:  BMJ       Date:  1991-10-05

Review 2.  Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature.

Authors:  T Meola; N A Soter; H W Lim
Journal:  Arch Dermatol       Date:  1991-11

3.  A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.

Authors:  C Jacobson; R C Cornell; R C Savin
Journal:  Cutis       Date:  1986-03

Review 4.  Cytokine system as potential target for antipsoriatic therapy.

Authors:  L Kemény; G Michel; A Dobozy; T Ruzicka
Journal:  Exp Dermatol       Date:  1994-02       Impact factor: 3.960

5.  Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp.

Authors:  L Hillström; L Pettersson; L Svensson
Journal:  J Int Med Res       Date:  1982       Impact factor: 1.671

6.  A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.

Authors:  E A Olsen; D L Cram; C N Ellis; J G Hickman; C Jacobson; E E Jenkins; A E Lasser; M Lebwohl; E Leibsohn; R S Medansky
Journal:  J Am Acad Dermatol       Date:  1991-03       Impact factor: 11.527

Review 7.  Topical corticosteroid therapy in psoriasis vulgaris.

Authors:  D J Trozak
Journal:  Cutis       Date:  1990-10

8.  Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate.

Authors:  C W Hanke; W D Steck; H H Roenigk
Journal:  Arch Dermatol       Date:  1979-09

9.  Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17,21-dipropionate: a double-blind comparison.

Authors:  A Lassus
Journal:  Curr Med Res Opin       Date:  1976       Impact factor: 2.580

10.  Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.

Authors:  H I Katz; J S Lindholm; J S Weiss; J S Shavin; M Morman; R Bressinck; R Cornell; D M Pariser; R J Pariser; W Weng
Journal:  Clin Ther       Date:  1995 May-Jun       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.